Genentech Inc. didn’t need to wait until Thanksgiving for the U.S. FDA to make up its mind. More than a month ahead of its PDUFA date, the agency approved the firm’s first-line breast cancer treatment ...

随着诺华三季报的披露，Pluvicto在今年前三季度中取得10.41亿美元的营收，成为全球首款销售额突破10亿美元的核药产品。Pluvicto的火爆，也让核药成为各大MNC的重点布局方向。

10月10日，晶泰科技旗下生物药发现业务线Ailux Biologics与强生公司下属Janssen Biotech, Inc.签署授权协议，协议的中心是晶泰科技自有生物AI平台。Ailux ...

生物技术公司Adaptimmune Therapeutics PLC (NASDAQ:ADAP)周五收到纳斯达克的通知，称该公司不符合最低投标价格要求。该公司的美国存托凭证（ADS）连续30个交易日的交易价格低于1.00美元的门槛，违反了纳斯达克上市规则5450 (a) (1)。

The potential blockbuster drug was approved by the agency more than a month before its scheduled decision date. A potential blockbuster cancer drug developed by Genentech Inc. and parent company ...

A four-year battle over one of the most ubiquitous patents in biotech ended with the US Patent and Trademark Office (USPTO) coming down on Genentech's side. The decision, reached in February ...

You are one of 7.5 million annual visitors to OpenSecrets. If you each donated just $1 a year, we'd never worry about funding again.

I previously compared the opportunities in CRISPR/Cas9 gene editing to be reminiscent of the golden years of biotech when ...

Good day and welcome to Adaptive Biotechnologies third quarter financial results. (Operator Instructions) As a reminder, this call may be recorded. I would like to turn the call over to Karina ...

在市场展现出非凡韧性的背景下，Sangamo BioSciences股票在投资者的热烈关注中触及52周高点，达到2.09美元。这一峰值对这家以开创性基因组疗法闻名的生物制药公司来说是一个重要里程碑。在过去一年里，Sangamo ...

Application error: a client-side exception has occurred (see the browser console for more information).